



Study **I**^2 Odds Ratio (95% Crl) Afatinib Cetuximab vs Afatinib 29 0.59 (0.18, 2.0) Pooled (pair-wise) 0.60 (0.12, 2.9) Indirect (back-calculated)Pooled NA 0.59 (0.086, 4.0) (network) Afatinib_HMGCRi vs Afatinib 40 1.5 (0.36, 6.4) Pooled (pair-wise) 1.5 (0.26, 9.4) Indirect (back-calculated) NA Pooled (network) 1.5 (0.20, 12.) **Chemotherapy vs Afatinib** 50 → 7.8e+10 (0.00015, 4.1e+25) Pooled (pair-wise) \rightarrow 8.4e+14 (2.5, 5.4e+63) Indirect (back-calculated) 0.99 (0.14, 6.8) Pooled (network) 1.0 (0.23, 11.) 52.4% **Erlotinib** vs Afatinib 38 0.36 (0.11, 1.2) Pooled (pair-wise) 0.38 (0.066, 1.7) 8.3e+04 (1.2e+02, 5.9e+07) Indirect (back-calculated) Pooled (network) 0.78 (0.20, 4.7) 92.5% **Gefitinib** vs Afatinib 48 1.9e+09 (3.1e-05, 1.2e+23) Pooled (pair-wise) 5.0e+12 (2.6, 1.9e+48) Indirect (back-calculated) 0.61 (0.059, 6.3) . . Pooled (network) 44.9% 0.65 (0.089, 9.5) 0.03 30









Study	I^2			Odds Ratio (95% Crl)
Erlotinib_METi vs Erlotinib				
12 39 7		<		3.0 (1.1, 8.1) 0.98 (0.029, 34.) 2.7 (0.13, 55.)
Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	0.0%		_ 	2.6 (0.80, 8.1) NA 2.4 (0.60, 9.1)
Erlotinib_MMPi vs Erlotir			_	2.4 (0.00, 9.1)
21 Pooled (pair-wise) Indirect (back-calculated) Pooled (network)		< • • • • • • • • • • • • • • • • • • •		0.36 (0.019, 7.2) 0.42 (0.0087, 6.6) NA 0.39 (0.0095, 7.3)
Erlotinib_antiangio vs Er	lotinib			
15 16 25 33 34 37			•— • • • • • • • • • • • • • • • • • •	2.6e+11 (1.3e-07, 5.2e+29) 1.2 (0.35, 4.3) 0.60 (0.32, 1.1) 0.44 (0.094, 2.0) 0.64 (0.16, 2.5)
Pooled (pair–wise) Indirect (back–calculated)	0.0%	-	_	1.5e-12 (1.9e-53, 1.2e+29) 0.71 (0.36, 1.6) NA
Pooled (network)	0.0%			0.70 (0.30, 1.8)
Placebo vs Erlotinib 30 46 58 Pooled (pair–wise) Indirect (back–calculated) Pooled (network)	53.6% 20.6%	<		9.4e-19 (6.2e-45, 1.4e+08) 0.66 (0.034, 13.) 1.6e-18 (2.1e-44, 1.2e+08) 0.15 (0.0042, 1.1) 0.53 (0.092, 3.0) 0.37 (0.065, 1.2)
		0.03 1	30	1

